CME/CE

Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activ...

Faculty: Kathryn Arbour This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addr...

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Faculty: Kathryn Arbour Faculty: Eileen M. O'Reilly, MD This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing cl...

Faculty: Marc Dweck, BSc, MBChB, PhD, FRCP, FRSE Faculty: Tomaz Podlesnikar, MD, PhD Faculty: Jeanette Schulz-Menger, MD This video series focuses on translating multimodality imaging into practical care for patients with hypertrophic cardiomyopathy (HCM). Expert faculty review echocardiography, cardiac magnetic resonance, and emerging imaging strategies to support diagnosis, guide HCM-specific th...

Faculty: Marc Dweck, BSc, MBChB, PhD, FRCP, FRSE Faculty: Tomaz Podlesnikar, MD, PhD Faculty: Jeanette Schulz-Menger, MD This video series focuses on translating multimodality imaging into practical care for patients with hypertrophic cardiomyopathy (HCM). Expert faculty review echocardiography, cardiac magnetic resonance, and emerging imaging strategies to support diagnosis, guide HCM-specific th...

Faculty: Kevin J Harrington, PhD, FRCP, FRCR, FRSB Faculty: Christophe Le Tourneau, MD, PhD This online educational activity highlights cutting-edge clinical trial data shaping the future of care in both locally advanced and recurrent/metastatic HNSCC. Experts review novel approaches such as perioperative immunotherapy, radioenhancers in the definitive setting, and next-generation targeted therapi...

Faculty: Kevin J Harrington, PhD, FRCP, FRCR, FRSB Faculty: Christophe Le Tourneau, MD, PhD This online educational activity highlights cutting-edge clinical trial data shaping the future of care in both locally advanced and recurrent/metastatic HNSCC. Experts review novel approaches such as perioperative immunotherapy, radioenhancers in the definitive setting, and next-generation targeted therapi...

Faculty: María-Victoria Mateos, MD, PhD This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that support this shift to use in early-line settings. Safety considerations, including infection risk and mitigation strategies, are addressed to guide real-w...

Faculty: María-Victoria Mateos, MD, PhD This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that support this shift to use in early-line settings. Safety considerations, including infection risk and mitigation strategies, are addressed to guide real-w...

Faculty: Richard E. Pratley, MD Faculty: David Cherney, MD, PhD Faculty: prof. Hiddo Heerspink Join Drs. Richard Pratley, David Cherney, and Hiddo Heerspink in this extended panel discussion, focused on results of the FINE-ONE clinical trial, which evaluated finerenone—a nonsteroidal mineralocorticoid receptor antagonist—in participants with type 1 diabetes and CKD. The dynamic conversation, which...

Faculty: Richard E. Pratley, MD Faculty: David Cherney, MD, PhD Faculty: prof. Hiddo Heerspink Join Drs. Richard Pratley, David Cherney, and Hiddo Heerspink in this extended panel discussion, focused on results of the FINE-ONE clinical trial, which evaluated finerenone—a nonsteroidal mineralocorticoid receptor antagonist—in participants with type 1 diabetes and CKD. The dynamic conversation, which...

Faculty: Jane Meisel, MD This online educational activity, derived from a live Grand Rounds event, focuses on the application of molecular testing, evidence-based therapy selection, and interdisciplinary collaboration in the management of high-risk early-stage breast cancer (EBC) with germline BRCA mutations. In this chapterized activity, Dr. Jane Meisel reviews practical approaches for implementi...

Faculty: Jane Meisel, MD This online educational activity, derived from a live Grand Rounds event, focuses on the application of molecular testing, evidence-based therapy selection, and interdisciplinary collaboration in the management of high-risk early-stage breast cancer (EBC) with germline BRCA mutations. In this chapterized activity, Dr. Jane Meisel reviews practical approaches for implementi...

Host: Suzanne E. Cuda, MD, MFOMA, FAAP, DABOM Guest: Jennifer Paisley, MD, FAAP, FOMA, Dipl ABOM On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes.

Host: Suzanne E. Cuda, MD, MFOMA, FAAP, DABOM Guest: Jennifer Paisley, MD, FAAP, FOMA, Dipl ABOM On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes.

Host: Marlana Orloff, MD Guest: Gregory Daniels, MD, PhD Guest: Jesse Keller, MD Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts...

Host: Flavia Castelino, MD Guest: Benjamin Korman, MD Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for ILD, PAH, and renal crisis, and apply risk stratification strategies to guide earlier intervention. Check out the evolving evidence o...

Host: Marlana Orloff, MD Guest: Gregory Daniels, MD, PhD Guest: Jesse Keller, MD Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts...

Host: Flavia Castelino, MD Guest: Benjamin Korman, MD Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for ILD, PAH, and renal crisis, and apply risk stratification strategies to guide earlier intervention. Check out the evolving evidence o...

Host: Ryan D. Cassaday, MD Guest: Daniel J. DeAngelo, MD, PhD Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patients continue to be treated with adul...

Host: Ryan D. Cassaday, MD Guest: Daniel J. DeAngelo, MD, PhD Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patients continue to be treated with adul...

Faculty: David Rubin, MD Faculty: Jennifer Geremia, PA-C This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The...